Assembly Biosciences Inc.

(ASMB) Trade

By |

Profile

Assembly Biosciences Inc is a clinical stage biotechnology company. It is advancing two innovative platform programs, a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.

Contact Information

Website: www.assemblybio.com
Email: lglaser@assemblybio.com
Main Phone: +1 317 210-9311
Address: 11711 North Meridian Street
Address 2: Suite 310
State: IN
City / Town: Carmel
Country: USA
Postal Code: 46032

Issuer Information

Exchange: NGS
CEO: John G McHutchison
Employees: 107
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Assembly Biosciences Inc is a clinical stage biotechnology company. It is advancing two innovative platform programs, a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.

Contact Information

Website: www.assemblybio.com
Email: lglaser@assemblybio.com
Main Phone: +1 317 210-9311
Address: 11711 North Meridian Street
Address 2: Suite 310
State: IN
City / Town: Carmel
Country: USA
Postal Code: 46032

Issuer Information

Exchange: NGS
CEO: John G McHutchison
Employees: 107
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 12.72 $ 3.42 (36.72%)
Last Price 12.72 Change $ 3.42 Change % 36.72 Tick N/A
Bid 12.72 Bid Size 100.00 Ask 13.32 Ask Size 100.00
Open 10.57 High 13.20 Low 10.53 Prev Close 9.30
Last Trade Volume 2.9 mi 52 Wk Hi 27.60 52 Wk Low 8.13
Market Cap 326.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 25,711,781.00 EPS (TTM) -3.67 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 18
Number of Buys 2 9
Number of Sells 2 9
Net Activity 0 24000
Last 10 Buys Shares
Derek Small 1,000
Derek Small 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
Last 10 Sell Shares
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 75 75 75 75
Low Target Price Estimate 42 42 42 42
Mean Target Price Estimate 55.67 55.67 55.67 55.67
Standard Deviation 17.21 17.21 17.21 17.21
Date of Most Recent Estimate 05/08/18 05/08/18 05/08/18 05/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2 2 2 2